AU2001242707A1 - Modified nodavirus rna for gene delivery - Google Patents

Modified nodavirus rna for gene delivery

Info

Publication number
AU2001242707A1
AU2001242707A1 AU2001242707A AU4270701A AU2001242707A1 AU 2001242707 A1 AU2001242707 A1 AU 2001242707A1 AU 2001242707 A AU2001242707 A AU 2001242707A AU 4270701 A AU4270701 A AU 4270701A AU 2001242707 A1 AU2001242707 A1 AU 2001242707A1
Authority
AU
Australia
Prior art keywords
modified
gene delivery
rna1
nodavirus rna
orf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001242707A
Other languages
English (en)
Inventor
Giuliano Bensi
Alessio Zippo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Publication of AU2001242707A1 publication Critical patent/AU2001242707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/102—Plasmid DNA for yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Wrappers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001242707A 2000-03-24 2001-03-26 Modified nodavirus rna for gene delivery Abandoned AU2001242707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0007231.4A GB0007231D0 (en) 2000-03-24 2000-03-24 Modified rna for gene delivery
GB0007231 2000-03-24
PCT/IB2001/000566 WO2001071017A2 (fr) 2000-03-24 2001-03-26 Arn de nodavirus modifie pour apport de gene

Publications (1)

Publication Number Publication Date
AU2001242707A1 true AU2001242707A1 (en) 2001-10-03

Family

ID=9888389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001242707A Abandoned AU2001242707A1 (en) 2000-03-24 2001-03-26 Modified nodavirus rna for gene delivery

Country Status (10)

Country Link
US (1) US7179457B2 (fr)
EP (1) EP1268833B1 (fr)
JP (2) JP4815091B2 (fr)
AT (1) ATE271613T1 (fr)
AU (1) AU2001242707A1 (fr)
CA (2) CA2711685C (fr)
DE (1) DE60104406T2 (fr)
ES (1) ES2225502T3 (fr)
GB (1) GB0007231D0 (fr)
WO (1) WO2001071017A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US9644188B2 (en) * 2013-04-17 2017-05-09 ALN Rao Methods and molecules for suppression of RNA silencing
CN116350803B (zh) * 2023-05-19 2023-11-24 健通(济南)生物科技有限公司 一种以乳头瘤病毒样颗粒为载体的mRNA递药系统及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
WO1998002548A2 (fr) 1996-07-17 1998-01-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules pseudovirales de papillomavirus infectieux
CA2329509C (fr) 1998-05-22 2009-10-06 Wisconsin Alumni Research Foundation Methodes et materiels ameliores de transformation
EP1105157B1 (fr) * 1998-08-14 2006-11-02 Merck & Co., Inc. Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus
AU5617200A (en) * 1999-06-14 2001-01-02 Uab Research Foundation, The Nodavirus-based dna expression vector and uses thereof

Also Published As

Publication number Publication date
WO2001071017A3 (fr) 2002-04-04
WO2001071017A2 (fr) 2001-09-27
US20030157130A1 (en) 2003-08-21
GB0007231D0 (en) 2000-05-17
ATE271613T1 (de) 2004-08-15
CA2711685C (fr) 2012-10-09
ES2225502T3 (es) 2005-03-16
DE60104406T2 (de) 2005-09-08
EP1268833B1 (fr) 2004-07-21
CA2711685A1 (fr) 2001-09-27
EP1268833A2 (fr) 2003-01-02
CA2400667A1 (fr) 2001-09-27
JP2011135897A (ja) 2011-07-14
CA2400667C (fr) 2010-10-19
JP2003527863A (ja) 2003-09-24
DE60104406D1 (de) 2004-08-26
US7179457B2 (en) 2007-02-20
JP4815091B2 (ja) 2011-11-16

Similar Documents

Publication Publication Date Title
WO2007127665A3 (fr) Nouvelles formulations stabilisant et inhibant la précipitation de compositions immunogènes
AP1872A (en) Virus-like particles of human papillomavirus.
EP2601969A3 (fr) Formulations de vaccin contre un norovirus
WO2010019262A3 (fr) Vaccin polyvalent
EP2261374A3 (fr) Procédé de prévention de la fusion virus-cellule en inhibant la fonction de la région d'initiation dans des virus à ARN dotés de protéines d'enveloppe fusiogène de membrane de classe I
WO2007052163A3 (fr) Vaccins viraux derives de cellules, presentant de faibles niveaux d'adn cellulaire residuel
WO2008011636A3 (fr) Administration de gène ciblée pour une vaccination des cellules dendritiques
WO2010059689A3 (fr) Vlp rsv f et procédés de fabrication et d'utilisation de celui-ci
WO2003048184A3 (fr) Vaccin a sous-unite de ns1 de flavivirus
EP1687329B8 (fr) Expression optimisee de hpv 58 l1 dans de la levure
WO2007044024A3 (fr) Vecteurs recombinants de la grippe avec des unites de transcription en tandem
WO2008024427A3 (fr) Plate-forme similaire à un virus pour une découverte de vaccin rapide
WO2004112831A3 (fr) Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique
WO2003092582A3 (fr) Enveloppes du virus ebola chimerique et utilisations pour ce dernier
ZA200710011B (en) A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
WO2009014782A3 (fr) Production améliorée et assemblage in vivo de particules icosaédriques solubles recombinées analogues à un virus
WO2004031210A3 (fr) Constructions optimisees a plusieurs epitopes et utilisations de ces dernieres
WO2006060257A3 (fr) Souches d'encapsidation bacteriennes utiles pour la generation et la production de nucleocapsides d'arn bicatenaire recombine et utilisations correspondantes
AU2001242707A1 (en) Modified nodavirus rna for gene delivery
SG159525A1 (en) Vaccine
WO2003072725A3 (fr) Systemes et vaccins d'expression d'arn a brin negatif recombinant
WO2009148229A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph
WO2005033265A3 (fr) Constructions multi-epitope optimisees et leurs utilisations
AU2002326925A1 (en) Process for preparing protease inhibitor intermediates
WO2009148230A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph